Literature DB >> 22441411

[Thrombosis prophylaxis in geriatric patients].

R E Roller1, P Feichtinger.   

Abstract

Older, multimorbid patients carry a high risk of suffering from a thromboembolic disease. The incidence of deep vein thrombosis in the outpatient setting is, depending on age, between 71 and 132 cases per 100,000 inhabitants and year. The rates increase significantly in the hospital setting and with increasing age. Today, pharmacological thrombolytic prophylaxis is the gold standard in patients needing surgical and internal medical care and is described in international evidence-based guidelines. However, the percentage of patients, who despite the guidelines do not receive pharmacological thrombolytic prophylaxis, is still very high. This is especially true for the group of multimorbid, very old patients. In the present work, the pathophysiological and clinical background for the increased susceptibility of thromboembolism in geriatric patients is summarized and the drugs currently available for pharmacological thromboembolic prophylaxis are presented. Hereby, special emphasis is placed on aspects of application in the elderly.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441411     DOI: 10.1007/s00391-012-0294-6

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  37 in total

1.  High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly.

Authors:  A van Hylckama Vlieg; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2003-12       Impact factor: 5.824

Review 2.  Challenges in the prevention of venous thromboembolism in the elderly.

Authors:  G Di Minno; A Tufano
Journal:  J Thromb Haemost       Date:  2004-08       Impact factor: 5.824

3.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.

Authors:  Alexander T Cohen; Bruce L Davidson; Alexander S Gallus; Michael R Lassen; Martin H Prins; Witold Tomkowski; Alexander G G Turpie; Jan F M Egberts; Anthonie W A Lensing
Journal:  BMJ       Date:  2006-01-26

4.  Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall.

Authors:  Brian F Gage; Elena Birman-Deych; Roger Kerzner; Martha J Radford; David S Nilasena; Michael W Rich
Journal:  Am J Med       Date:  2005-06       Impact factor: 4.965

5.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study.

Authors:  John A Heit; W Michael O'Fallon; Tanya M Petterson; Christine M Lohse; Marc D Silverstein; David N Mohr; L Joseph Melton
Journal:  Arch Intern Med       Date:  2002-06-10

6.  A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.

Authors:  Harry R Buller; Anthonie W A Lensing; Martin H Prins; Giancarlo Agnelli; Alexander Cohen; Alexander S Gallus; Frank Misselwitz; Gary Raskob; Sebastian Schellong; Annelise Segers
Journal:  Blood       Date:  2008-07-11       Impact factor: 22.113

7.  Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Gordon H Guyatt; Deborah J Cook; Roman Jaeschke; Stephen G Pauker; Holger J Schünemann
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 8.  D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review.

Authors:  Paul D Stein; Russell D Hull; Kalpesh C Patel; Ronald E Olson; William A Ghali; Rollin Brant; Rita K Biel; Vinay Bharadia; Neeraj K Kalra
Journal:  Ann Intern Med       Date:  2004-04-20       Impact factor: 25.391

9.  Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.

Authors:  H Buller; D Deitchman; M Prins; A Segers
Journal:  J Thromb Haemost       Date:  2008-06-06       Impact factor: 5.824

10.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

Authors:  H R Büller; B L Davidson; H Decousus; A Gallus; M Gent; F Piovella; M H Prins; G Raskob; A E M van den Berg-Segers; R Cariou; O Leeuwenkamp; A W A Lensing
Journal:  N Engl J Med       Date:  2003-10-30       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.